Board of Directors
Barry R. Frankel
Barry R. Frankel is a Managing Director at Frankel Group LLC, a management consulting firm that provides strategic and transactional advisory services to the global life sciences industry and growth equity/banking firms servicing the industry. Prior to founding Frankel Group LLC in 1993, Mr. Frankel was President of SJ Weinstein Associates, a health care marketing strategy and communications firm. Before joining SJ Weinstein Associates, Mr. Frankel held various strategy and operating positions at Pfizer Pharmaceuticals and was a Senior Investment Research Officer for life science investments at Citibank.
Mr. Frankel is also a director of Inspiration Biopharmaceuticals. In addition, Mr. Frankel is a member of the Pfizer Specialty Products Advisory Board and serves as an advisor to the Rutgers Center for Innovation and Emerging Technology (CIVET).
Mr. Frankel holds an MBA, with Distinction, from The Wharton School of The University of Pennsylvania, and a BS, Summa Cum Laude, in Engineering from Rutgers University.
Andrew R. Hilgenbrink, Ph.D.
Andrew R. Hilgenbrink is a Director at Cummings Bay Capital Management, L.P., an affiliated registered investment adviser of Highland Capital Management, L.P. He is a manager of a dedicated Healthcare portfolio where his expertise lies in the biotechnology and life science sectors. Prior to joining Cummings Bay, he spent four years as a healthcare equity analyst at Jefferies & Company. During his tenure at Jefferies he covered stocks in a variety of healthcare sectors including specialty pharmaceuticals, pharmaceutical services, managed care, and healthcare information technology. Dr. Hilgenbrink has been actively investing in the biotechnology sector for over ten years to which he brings experience from the corporate environment combined with an investment management perspective.
Dr. Hilgenbrink holds a Doctorate of Chemistry from Purdue University and an MBA from the Owen Graduate School of Management at Vanderbilt University. He completed his BS in Biochemistry from the University of Missouri.
Leslie D. Michelson
Leslie D. Michelson is Chairman of the Board and Chief Executive Officer of Private Health Management, Inc., which provides a retainer-based service to coordinate the provision of their highest quality preventive, diagnostic, therapeutic and emergency care services for patients around the world.
From 2002-2006 Mr. Michelson served as Chief Executive Officer of the Prostate Cancer Foundation, the world’s largest source of philanthropic support for prostate cancer research. Prior to joining the Prostate Cancer Foundation, he served as Chief Executive Officer of Acurian, a company which recruits patients and physicians for participation in clinical trials. He also co-founded and served as Chairman and Chief Executive Officer of Value Health Sciences, one of the first disease management companies. He then co-founded and served as Chairman and co-Chief Executive Officer of Protocare, a provider of clinical trials site and disease management services to the biotechnology and pharmaceutical industries.
Mr. Michelson served as Special Assistant to the General Counsel of the U.S. Department of Health and Human Services during the Carter Administration. He then joined a private equity firm focused on healthcare and real estate investments.
Mr. Michelson is also a director of several real estate investment trusts sponsored by American Realty Capital. Mr. Michelson is also a director of the Prostate Cancer Foundation and the ALS Therapy Development Institute, a non-profit research and development institute.
Mr. Michelson received a BA from The Johns Hopkins University and a JD from Yale Law School.
Carl Moore is a Managing Director in the Private Equity Strategy and Operations Team at Highland Capital Management, L.P. Prior to assuming the role of Managing Director, Mr. Moore served as a Restructuring Counsel and Portfolio Manager in the firm’s Distressed group from 2008-2010, and as a Portfolio Manager in the firm’s Private Equity group from 2006 to 2007. Mr. Moore joined Highland in 2003 as a Portfolio Analyst in the firm’s distressed investment team with a focus on technology and healthcare investments. Prior to joining Highland, he worked as an associate at the law firm Brobeck, Phleger and Harrison, L.L.P. in Austin, Texas where his practice was focused on private equity transactions, public offerings, mergers and acquisitions, and general corporate matters for startup and emerging growth technology companies. Mr. Moore began his career as a licensed CPA in the Tax section of Coopers & Lybrand.
Mr. Moore currently serves on the Board of Directors of Carey International, Inc., Epocal, Inc., and Trussway Holdings, Inc. (Chairman).
Mr. Moore received a JD from the University of Houston, School of Law and a BA in Plan II-Liberal Arts and a BBA in Finance from the University of Texas at Austin. He is currently a member of the Texas State Bar Association.
Nelson K. Stacks
CHIEF EXECUTIVE OFFICER
Nelson K. Stacks was appointed Chief Executive Officer and Director of Molecular Insight in July 2012. He joined the Company as the Interim CEO and Executive Director in December 2011. Mr. Stacks is also a Director of Wave Guide Technology, a medical diagnostic company with the first-of-its kind of hand-held Nuclear Magnetic Resonance machine to diagnose cancer and other disease states at point of care. Prior to that, Mr. Stacks was President and Chief Executive Officer of Vascular Pathways Incorporated, a medical device company focused on peripheral IV, where he raised capital from leading Venture Capital groups and brought the company through regulatory requirements and also initiated manufacturing of high-volume, complex products.
Mr. Stacks has also served as Board Chairman and Director at XBIO, as the Executive Director and CEO at Xenome Limited, and as a General Partner with the British Venture Capital firm, 3i Plc. From 2006-2008 he was Chief Executive Officer and a Director of Telesso Technologies. Mr. Stacks started his career as a Principal/Kauffman Fellow at Oak Investment Partners. He has investor experience in all areas of healthcare and information technology, and operating experience across multiple healthcare platforms including therapeutics, devices, and services.
Mr. Stacks received his BA from the University of Rochester and his MBA from the Franklin W. Olin Graduate School of Business at Babson College.